A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.
BMS’ Phase 3 win for lung drug clouded by high-dose miss Read More »
The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win Read More »
Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.
RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish Read More »
Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial supply. The investment will create more than 300 new jobs over the next five years, Pennsylvania state officials said.
GSK pledges $800M to add biologics production capabilities in Pennsylvania Read More »
70% of Gen Z healthcare workers are looking to leave. What will convince them to stay?
What Gen Z healthcare workers are really looking for Read More »
See how workforce and care patterns can sharpen growth decisions beyond a health plan’s service area.
La Neurociencia del Riesgo: Lo Que el Nobel de Medicina 2026 Revela Sobre Por Qué Nos Enganchan las Tragamonedas El lunes 5 de octubre, el Comité Nobel anunció que Karl Deisseroth, Peter Hegemann y Georg Nagel se llevaban el premio de Medicina 2026. El motivo: una herra …
Nobel de Medicina 2026: La Ciencia Detrás del Enganche Read More »
Decir que alguien “habla inglés fluido” o que tiene un “nivel avanzado” es ambiguo. En el ámbito académico y laboral, las apreciaciones subjetivas no sirven para tomar decisiones de admisión o contratación. Por esa razón, la evaluaci&oacu …
CDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration built on shared risk, regulatory fluency and technical insight. As rising compliance pressure and geopolitical volatility reshape manufacturing, partners like Rose BioSolutions argue that true value now comes from challenging assumptions, anticipating hurdles and protecting programs before problems surface.
Successful CDMO partnerships hinge on honest—and sometimes critical—support Read More »
John Stenson from Malvern Panalytical explains why integrating multiple stability measurements onto a single platform is the route to success in early-stage biologics testing.
How to boost throughput and data quality for stability testing of biologics Read More »
